# ARTEMIS-003: HS-20093 in Patients With Metastatic Castrate-resistant Prostate Cancer (mCRPC) and Advanced Solid Tumors

> **NCT06001255** · PHASE2 · RECRUITING · sponsor: **Hansoh BioMedical R&D Company** · enrollment: 120 (estimated)

## Conditions studied

- Metastasis Castration Resistant Prostate Cancer(mCRPC)

## Interventions

- **DRUG:** HS-20093

## Key facts

- **NCT ID:** NCT06001255
- **Lead sponsor:** Hansoh BioMedical R&D Company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-01-18
- **Primary completion:** 2024-12-31
- **Final completion:** 2025-12-31
- **Target enrollment:** 120 (ESTIMATED)
- **Last updated:** 2024-08-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06001255

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06001255, "ARTEMIS-003: HS-20093 in Patients With Metastatic Castrate-resistant Prostate Cancer (mCRPC) and Advanced Solid Tumors". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT06001255. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*